Glepaglutide: Risks & Legal Status

Critical Safety Information#

Glepaglutide (ZP1848) is an investigational GLP-2 analog that has not been approved by any regulatory authority. The FDA issued a Complete Response Letter in December 2024 for the short bowel syndrome New Drug Application, finding that the data did not meet the full requirements for substantial evidence of efficacy and safety at the to-be-marketed dose. All safety information is derived from clinical trials.

Investigational Status Risk#

The primary risk context for glepaglutide is its regulatory uncertainty:

• The FDA CRL specifically cited insufficient evidence at the to-be-marketed dose
• The once-weekly dosing arm in the pivotal phase 3 trial failed to achieve statistical significance
• An additional phase 3 trial (EASE SBS 3) is planned for 2025 to provide confirmatory data
• The European Marketing Authorization Application is still planned, pending additional data
• Patients have access only through clinical trial enrollment

Intestinal Neoplasm Risk#

As a GLP-2 receptor agonist, glepaglutide stimulates intestinal crypt cell proliferation. This creates a theoretical risk:

Polyp Promotion#

• GLP-2 promotes intestinal epithelial cell growth, which could theoretically accelerate growth of pre-existing polyps or neoplasms
• Teduglutide (the approved GLP-2 analog) carries a boxed warning regarding this risk
• No intestinal malignancies have been attributed to glepaglutide in clinical trials, but long-term data are limited
• The same precautionary principle applies to all GLP-2 analogs

Colonoscopy Surveillance#

• Colonoscopy is recommended at baseline (within 6 months of starting treatment)
• Periodic surveillance colonoscopies during treatment
• Any intestinal polyps should be removed prior to GLP-2 analog initiation
• Active intestinal malignancy is a contraindication

Fluid Management Risk#

Glepaglutide increases intestinal fluid absorption, which creates a specific clinical risk:

• If parenteral support volumes are not reduced to match improved absorption, fluid overload may occur
• Peripheral edema was reported in ~56% of patients
• PS adjustment must be done gradually under specialist supervision
• Monitoring of fluid balance, body weight, and serum electrolytes is essential
• Abrupt PS discontinuation is not recommended even in patients approaching enteral autonomy

Regulatory and Legal Status#

Glepaglutide is not approved for use in any country.

Zealand Pharma (Copenhagen, Denmark) is the sponsor of the global development program. VectivBio, which previously held rights to glepaglutide, was acquired by Zealand Pharma.

Risk Mitigation#

For Clinical Trial Investigators#

1. Perform baseline colonoscopy and remove any polyps before treatment initiation
2. Monitor parenteral support requirements closely and reduce volumes gradually
3. Track fluid balance, body weight, serum electrolytes, and renal function
4. Monitor for GI symptoms (nausea, abdominal pain, stoma complications)
5. Rotate injection sites to minimize injection site reactions
6. Perform periodic surveillance colonoscopy during treatment

For Patients in Clinical Trials#

1. Report any new abdominal symptoms, changes in stoma output, or signs of fluid retention
2. Do not adjust parenteral support volumes without medical guidance
3. Attend all scheduled monitoring visits and colonoscopy appointments
4. Understand that treatment benefit is expected to be dependent on continued dosing

Related Reading#

• Glepaglutide overview and research guide
• Glepaglutide side effects profile
• Glepaglutide research evidence